

Global Idiopathic Hypersomnia Treatment Market Research Report 2023

<https://marketpublishers.com/r/G18FEE95CB25EN.html>

Date: December 2023

Pages: 85

Price: US\$ 2,900.00 (Single User License)

ID: G18FEE95CB25EN

Abstracts

Idiopathic hypersomnia (IH) is a rare sleep disorder marked by an over sleeping duration time during the day even after a longer sleeping hours of night sleep. People with idiopathic hypersomnia sleep normal or for long hours each night but still feel excessively sleepy during the day. Idiopathic hypersomnia is a type of hypersomnia and symptoms include chronic excessive daytime sleepiness (EDS), non-refreshing daytime napping, sleep drunkenness after nighttime sleep, naps, and others. Idiopathic hypersomnia is a nervous system disease, whose cause is not known. There is no single drug available that is approved by the U.S. FDA for this disease, but medicines such as dextroamphetamine that are approved for narcolepsy, one of the types of hypersomnia can be used for idiopathic hypersomnia off-label.

According to QYResearch's new survey, global Idiopathic Hypersomnia Treatment market is projected to reach US\$ million in 2029, increasing from US\$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Idiopathic Hypersomnia Treatment market research.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for

drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Idiopathic Hypersomnia Treatment market with multiple angles, which provides sufficient supports to readers' strategy and decision making.

By Company

Takeda Pharmaceutical

Teva Pharmaceutical Industries

Jazz Pharmaceuticals

BIOPROJET

Avadel Pharmaceuticals

GlaxoSmithKline

Pfizer

Theranexus

Fisher and Paykel Healthcare

Drive DeVilbiss Healthcare

Merck

Segment by Type

Stimulant Medications

Non-Stimulant Wake-Promoting Medications

Sodium Oxybate

Segment by Application

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

The Idiopathic Hypersomnia Treatment report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)

Chapter 2: Global market size, regional market size. Market Opportunities and Challenges

Chapter 3: Companies' Competition Patterns

Chapter 4: Product Type Analysis

Chapter 5: Product Application Analysis

Chapter 6 to 10: Country Level Value Analysis

Chapter 11: Companies' Outline

Chapter 12: Market Conclusions

Chapter 13: Research Methodology and Data Source

Contents

1 REPORT OVERVIEW

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Idiopathic Hypersomnia Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Stimulant Medications

1.2.3 Non-Stimulant Wake-Promoting Medications

1.2.4 Sodium Oxybate

1.3 Market by Application

1.3.1 Global Idiopathic Hypersomnia Treatment Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Hospital Pharmacies

1.3.3 Retail Pharmacies

1.3.4 Online Pharmacies

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 GLOBAL GROWTH TRENDS

2.1 Global Idiopathic Hypersomnia Treatment Market Perspective (2018-2029)

2.2 Idiopathic Hypersomnia Treatment Growth Trends by Region

2.2.1 Global Idiopathic Hypersomnia Treatment Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Idiopathic Hypersomnia Treatment Historic Market Size by Region (2018-2023)

2.2.3 Idiopathic Hypersomnia Treatment Forecasted Market Size by Region (2024-2029)

2.3 Idiopathic Hypersomnia Treatment Market Dynamics

2.3.1 Idiopathic Hypersomnia Treatment Industry Trends

2.3.2 Idiopathic Hypersomnia Treatment Market Drivers

2.3.3 Idiopathic Hypersomnia Treatment Market Challenges

2.3.4 Idiopathic Hypersomnia Treatment Market Restraints

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Idiopathic Hypersomnia Treatment Players by Revenue

- 3.1.1 Global Top Idiopathic Hypersomnia Treatment Players by Revenue (2018-2023)
- 3.1.2 Global Idiopathic Hypersomnia Treatment Revenue Market Share by Players (2018-2023)
- 3.2 Global Idiopathic Hypersomnia Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.3 Players Covered: Ranking by Idiopathic Hypersomnia Treatment Revenue
- 3.4 Global Idiopathic Hypersomnia Treatment Market Concentration Ratio
 - 3.4.1 Global Idiopathic Hypersomnia Treatment Market Concentration Ratio (CR5 and HHI)
 - 3.4.2 Global Top 10 and Top 5 Companies by Idiopathic Hypersomnia Treatment Revenue in 2022
- 3.5 Idiopathic Hypersomnia Treatment Key Players Head office and Area Served
- 3.6 Key Players Idiopathic Hypersomnia Treatment Product Solution and Service
- 3.7 Date of Enter into Idiopathic Hypersomnia Treatment Market
- 3.8 Mergers & Acquisitions, Expansion Plans

4 IDIOPATHIC HYPERSOMNIA TREATMENT BREAKDOWN DATA BY TYPE

- 4.1 Global Idiopathic Hypersomnia Treatment Historic Market Size by Type (2018-2023)
- 4.2 Global Idiopathic Hypersomnia Treatment Forecasted Market Size by Type (2024-2029)

5 IDIOPATHIC HYPERSOMNIA TREATMENT BREAKDOWN DATA BY APPLICATION

- 5.1 Global Idiopathic Hypersomnia Treatment Historic Market Size by Application (2018-2023)
- 5.2 Global Idiopathic Hypersomnia Treatment Forecasted Market Size by Application (2024-2029)

6 NORTH AMERICA

- 6.1 North America Idiopathic Hypersomnia Treatment Market Size (2018-2029)
- 6.2 North America Idiopathic Hypersomnia Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 6.3 North America Idiopathic Hypersomnia Treatment Market Size by Country (2018-2023)
- 6.4 North America Idiopathic Hypersomnia Treatment Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7 EUROPE

7.1 Europe Idiopathic Hypersomnia Treatment Market Size (2018-2029)

7.2 Europe Idiopathic Hypersomnia Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Idiopathic Hypersomnia Treatment Market Size by Country (2018-2023)

7.4 Europe Idiopathic Hypersomnia Treatment Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 ASIA-PACIFIC

8.1 Asia-Pacific Idiopathic Hypersomnia Treatment Market Size (2018-2029)

8.2 Asia-Pacific Idiopathic Hypersomnia Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Idiopathic Hypersomnia Treatment Market Size by Region (2018-2023)

8.4 Asia-Pacific Idiopathic Hypersomnia Treatment Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 LATIN AMERICA

9.1 Latin America Idiopathic Hypersomnia Treatment Market Size (2018-2029)

9.2 Latin America Idiopathic Hypersomnia Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Idiopathic Hypersomnia Treatment Market Size by Country (2018-2023)

9.4 Latin America Idiopathic Hypersomnia Treatment Market Size by Country

(2024-2029)

9.5 Mexico

9.6 Brazil

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa Idiopathic Hypersomnia Treatment Market Size (2018-2029)

10.2 Middle East & Africa Idiopathic Hypersomnia Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Idiopathic Hypersomnia Treatment Market Size by Country (2018-2023)

10.4 Middle East & Africa Idiopathic Hypersomnia Treatment Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 KEY PLAYERS PROFILES

11.1 Takeda Pharmaceutical

11.1.1 Takeda Pharmaceutical Company Detail

11.1.2 Takeda Pharmaceutical Business Overview

11.1.3 Takeda Pharmaceutical Idiopathic Hypersomnia Treatment Introduction

11.1.4 Takeda Pharmaceutical Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)

11.1.5 Takeda Pharmaceutical Recent Development

11.2 Teva Pharmaceutical Industries

11.2.1 Teva Pharmaceutical Industries Company Detail

11.2.2 Teva Pharmaceutical Industries Business Overview

11.2.3 Teva Pharmaceutical Industries Idiopathic Hypersomnia Treatment Introduction

11.2.4 Teva Pharmaceutical Industries Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)

11.2.5 Teva Pharmaceutical Industries Recent Development

11.3 Jazz Pharmaceuticals

11.3.1 Jazz Pharmaceuticals Company Detail

11.3.2 Jazz Pharmaceuticals Business Overview

11.3.3 Jazz Pharmaceuticals Idiopathic Hypersomnia Treatment Introduction

11.3.4 Jazz Pharmaceuticals Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)

- 11.3.5 Jazz Pharmaceuticals Recent Development
- 11.4 BIOPROJET
 - 11.4.1 BIOPROJET Company Detail
 - 11.4.2 BIOPROJET Business Overview
 - 11.4.3 BIOPROJET Idiopathic Hypersomnia Treatment Introduction
 - 11.4.4 BIOPROJET Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)
 - 11.4.5 BIOPROJET Recent Development
- 11.5 Avadel Pharmaceuticals
 - 11.5.1 Avadel Pharmaceuticals Company Detail
 - 11.5.2 Avadel Pharmaceuticals Business Overview
 - 11.5.3 Avadel Pharmaceuticals Idiopathic Hypersomnia Treatment Introduction
 - 11.5.4 Avadel Pharmaceuticals Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)
 - 11.5.5 Avadel Pharmaceuticals Recent Development
- 11.6 GlaxoSmithKline
 - 11.6.1 GlaxoSmithKline Company Detail
 - 11.6.2 GlaxoSmithKline Business Overview
 - 11.6.3 GlaxoSmithKline Idiopathic Hypersomnia Treatment Introduction
 - 11.6.4 GlaxoSmithKline Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)
 - 11.6.5 GlaxoSmithKline Recent Development
- 11.7 Pfizer
 - 11.7.1 Pfizer Company Detail
 - 11.7.2 Pfizer Business Overview
 - 11.7.3 Pfizer Idiopathic Hypersomnia Treatment Introduction
 - 11.7.4 Pfizer Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)
 - 11.7.5 Pfizer Recent Development
- 11.8 Theranexus
 - 11.8.1 Theranexus Company Detail
 - 11.8.2 Theranexus Business Overview
 - 11.8.3 Theranexus Idiopathic Hypersomnia Treatment Introduction
 - 11.8.4 Theranexus Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)
 - 11.8.5 Theranexus Recent Development
- 11.9 Fisher and Paykel Healthcare
 - 11.9.1 Fisher and Paykel Healthcare Company Detail
 - 11.9.2 Fisher and Paykel Healthcare Business Overview
 - 11.9.3 Fisher and Paykel Healthcare Idiopathic Hypersomnia Treatment Introduction

11.9.4 Fisher and Paykel Healthcare Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)

11.9.5 Fisher and Paykel Healthcare Recent Development

11.10 Drive DeVilbiss Healthcare

11.10.1 Drive DeVilbiss Healthcare Company Detail

11.10.2 Drive DeVilbiss Healthcare Business Overview

11.10.3 Drive DeVilbiss Healthcare Idiopathic Hypersomnia Treatment Introduction

11.10.4 Drive DeVilbiss Healthcare Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)

11.10.5 Drive DeVilbiss Healthcare Recent Development

11.11 Merck

11.11.1 Merck Company Detail

11.11.2 Merck Business Overview

11.11.3 Merck Idiopathic Hypersomnia Treatment Introduction

11.11.4 Merck Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023)

11.11.5 Merck Recent Development

12 ANALYST'S VIEWPOINTS/CONCLUSIONS

13 APPENDIX

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List Of Tables

LIST OF TABLES

- Table 1. Global Idiopathic Hypersomnia Treatment Market Size Growth Rate by Type (US\$ Million): 2018 VS 2022 VS 2029
- Table 2. Key Players of Stimulant Medications
- Table 3. Key Players of Non-Stimulant Wake-Promoting Medications
- Table 4. Key Players of Sodium Oxybate
- Table 5. Global Idiopathic Hypersomnia Treatment Market Size Growth by Application (US\$ Million): 2018 VS 2022 VS 2029
- Table 6. Global Idiopathic Hypersomnia Treatment Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029
- Table 7. Global Idiopathic Hypersomnia Treatment Market Size by Region (2018-2023) & (US\$ Million)
- Table 8. Global Idiopathic Hypersomnia Treatment Market Share by Region (2018-2023)
- Table 9. Global Idiopathic Hypersomnia Treatment Forecasted Market Size by Region (2024-2029) & (US\$ Million)
- Table 10. Global Idiopathic Hypersomnia Treatment Market Share by Region (2024-2029)
- Table 11. Idiopathic Hypersomnia Treatment Market Trends
- Table 12. Idiopathic Hypersomnia Treatment Market Drivers
- Table 13. Idiopathic Hypersomnia Treatment Market Challenges
- Table 14. Idiopathic Hypersomnia Treatment Market Restraints
- Table 15. Global Idiopathic Hypersomnia Treatment Revenue by Players (2018-2023) & (US\$ Million)
- Table 16. Global Idiopathic Hypersomnia Treatment Market Share by Players (2018-2023)
- Table 17. Global Top Idiopathic Hypersomnia Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Idiopathic Hypersomnia Treatment as of 2022)
- Table 18. Ranking of Global Top Idiopathic Hypersomnia Treatment Companies by Revenue (US\$ Million) in 2022
- Table 19. Global 5 Largest Players Market Share by Idiopathic Hypersomnia Treatment Revenue (CR5 and HHI) & (2018-2023)
- Table 20. Key Players Headquarters and Area Served
- Table 21. Key Players Idiopathic Hypersomnia Treatment Product Solution and Service
- Table 22. Date of Enter into Idiopathic Hypersomnia Treatment Market

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Idiopathic Hypersomnia Treatment Market Size by Type (2018-2023) & (US\$ Million)

Table 25. Global Idiopathic Hypersomnia Treatment Revenue Market Share by Type (2018-2023)

Table 26. Global Idiopathic Hypersomnia Treatment Forecasted Market Size by Type (2024-2029) & (US\$ Million)

Table 27. Global Idiopathic Hypersomnia Treatment Revenue Market Share by Type (2024-2029)

Table 28. Global Idiopathic Hypersomnia Treatment Market Size by Application (2018-2023) & (US\$ Million)

Table 29. Global Idiopathic Hypersomnia Treatment Revenue Market Share by Application (2018-2023)

Table 30. Global Idiopathic Hypersomnia Treatment Forecasted Market Size by Application (2024-2029) & (US\$ Million)

Table 31. Global Idiopathic Hypersomnia Treatment Revenue Market Share by Application (2024-2029)

Table 32. North America Idiopathic Hypersomnia Treatment Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 33. North America Idiopathic Hypersomnia Treatment Market Size by Country (2018-2023) & (US\$ Million)

Table 34. North America Idiopathic Hypersomnia Treatment Market Size by Country (2024-2029) & (US\$ Million)

Table 35. Europe Idiopathic Hypersomnia Treatment Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 36. Europe Idiopathic Hypersomnia Treatment Market Size by Country (2018-2023) & (US\$ Million)

Table 37. Europe Idiopathic Hypersomnia Treatment Market Size by Country (2024-2029) & (US\$ Million)

Table 38. Asia-Pacific Idiopathic Hypersomnia Treatment Market Size Growth Rate by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 39. Asia-Pacific Idiopathic Hypersomnia Treatment Market Size by Region (2018-2023) & (US\$ Million)

Table 40. Asia-Pacific Idiopathic Hypersomnia Treatment Market Size by Region (2024-2029) & (US\$ Million)

Table 41. Latin America Idiopathic Hypersomnia Treatment Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 42. Latin America Idiopathic Hypersomnia Treatment Market Size by Country (2018-2023) & (US\$ Million)

Table 43. Latin America Idiopathic Hypersomnia Treatment Market Size by Country (2024-2029) & (US\$ Million)

Table 44. Middle East & Africa Idiopathic Hypersomnia Treatment Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 45. Middle East & Africa Idiopathic Hypersomnia Treatment Market Size by Country (2018-2023) & (US\$ Million)

Table 46. Middle East & Africa Idiopathic Hypersomnia Treatment Market Size by Country (2024-2029) & (US\$ Million)

Table 47. Takeda Pharmaceutical Company Detail

Table 48. Takeda Pharmaceutical Business Overview

Table 49. Takeda Pharmaceutical Idiopathic Hypersomnia Treatment Product

Table 50. Takeda Pharmaceutical Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US\$ Million)

Table 51. Takeda Pharmaceutical Recent Development

Table 52. Teva Pharmaceutical Industries Company Detail

Table 53. Teva Pharmaceutical Industries Business Overview

Table 54. Teva Pharmaceutical Industries Idiopathic Hypersomnia Treatment Product

Table 55. Teva Pharmaceutical Industries Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US\$ Million)

Table 56. Teva Pharmaceutical Industries Recent Development

Table 57. Jazz Pharmaceuticals Company Detail

Table 58. Jazz Pharmaceuticals Business Overview

Table 59. Jazz Pharmaceuticals Idiopathic Hypersomnia Treatment Product

Table 60. Jazz Pharmaceuticals Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US\$ Million)

Table 61. Jazz Pharmaceuticals Recent Development

Table 62. BIOPROJET Company Detail

Table 63. BIOPROJET Business Overview

Table 64. BIOPROJET Idiopathic Hypersomnia Treatment Product

Table 65. BIOPROJET Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US\$ Million)

Table 66. BIOPROJET Recent Development

Table 67. Avadel Pharmaceuticals Company Detail

Table 68. Avadel Pharmaceuticals Business Overview

Table 69. Avadel Pharmaceuticals Idiopathic Hypersomnia Treatment Product

Table 70. Avadel Pharmaceuticals Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US\$ Million)

Table 71. Avadel Pharmaceuticals Recent Development

Table 72. GlaxoSmithKline Company Detail

Table 73. GlaxoSmithKline Business Overview

Table 74. GlaxoSmithKline Idiopathic Hypersomnia Treatment Product

Table 75. GlaxoSmithKline Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US\$ Million)

Table 76. GlaxoSmithKline Recent Development

Table 77. Pfizer Company Detail

Table 78. Pfizer Business Overview

Table 79. Pfizer Idiopathic Hypersomnia Treatment Product

Table 80. Pfizer Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US\$ Million)

Table 81. Pfizer Recent Development

Table 82. Theranexus Company Detail

Table 83. Theranexus Business Overview

Table 84. Theranexus Idiopathic Hypersomnia Treatment Product

Table 85. Theranexus Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US\$ Million)

Table 86. Theranexus Recent Development

Table 87. Fisher and Paykel Healthcare Company Detail

Table 88. Fisher and Paykel Healthcare Business Overview

Table 89. Fisher and Paykel Healthcare Idiopathic Hypersomnia Treatment Product

Table 90. Fisher and Paykel Healthcare Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US\$ Million)

Table 91. Fisher and Paykel Healthcare Recent Development

Table 92. Drive DeVilbiss Healthcare Company Detail

Table 93. Drive DeVilbiss Healthcare Business Overview

Table 94. Drive DeVilbiss Healthcare Idiopathic Hypersomnia Treatment Product

Table 95. Drive DeVilbiss Healthcare Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US\$ Million)

Table 96. Drive DeVilbiss Healthcare Recent Development

Table 97. Merck Company Detail

Table 98. Merck Business Overview

Table 99. Merck Idiopathic Hypersomnia Treatment Product

Table 100. Merck Revenue in Idiopathic Hypersomnia Treatment Business (2018-2023) & (US\$ Million)

Table 101. Merck Recent Development

Table 102. Research Programs/Design for This Report

Table 103. Key Data Information from Secondary Sources

Table 104. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Idiopathic Hypersomnia Treatment Market Size Comparison by Type (2023-2029) & (US\$ Million)

Figure 2. Global Idiopathic Hypersomnia Treatment Market Share by Type: 2022 VS 2029

Figure 3. Stimulant Medications Features

Figure 4. Non-Stimulant Wake-Promoting Medications Features

Figure 5. Sodium Oxybate Features

Figure 6. Global Idiopathic Hypersomnia Treatment Market Size Comparison by Application (2023-2029) & (US\$ Million)

Figure 7. Global Idiopathic Hypersomnia Treatment Market Share by Application: 2022 VS 2029

Figure 8. Hospital Pharmacies Case Studies

Figure 9. Retail Pharmacies Case Studies

Figure 10. Online Pharmacies Case Studies

Figure 11. Idiopathic Hypersomnia Treatment Report Years Considered

Figure 12. Global Idiopathic Hypersomnia Treatment Market Size (US\$ Million), Year-over-Year: 2018-2029

Figure 13. Global Idiopathic Hypersomnia Treatment Market Size, (US\$ Million), 2018 VS 2022 VS 2029

Figure 14. Global Idiopathic Hypersomnia Treatment Market Share by Region: 2022 VS 2029

Figure 15. Global Idiopathic Hypersomnia Treatment Market Share by Players in 2022

Figure 16. Global Top Idiopathic Hypersomnia Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Idiopathic Hypersomnia Treatment as of 2022)

Figure 17. The Top 10 and 5 Players Market Share by Idiopathic Hypersomnia Treatment Revenue in 2022

Figure 18. North America Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 19. North America Idiopathic Hypersomnia Treatment Market Share by Country (2018-2029)

Figure 20. United States Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 21. Canada Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 22. Europe Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 23. Europe Idiopathic Hypersomnia Treatment Market Share by Country (2018-2029)

Figure 24. Germany Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 25. France Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 26. U.K. Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 27. Italy Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 28. Russia Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 29. Nordic Countries Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 30. Asia-Pacific Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 31. Asia-Pacific Idiopathic Hypersomnia Treatment Market Share by Region (2018-2029)

Figure 32. China Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 33. Japan Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 34. South Korea Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 35. Southeast Asia Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 36. India Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 37. Australia Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 38. Latin America Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 39. Latin America Idiopathic Hypersomnia Treatment Market Share by Country (2018-2029)

Figure 40. Mexico Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 41. Brazil Idiopathic Hypersomnia Treatment Market Size YoY Growth

(2018-2029) & (US\$ Million)

Figure 42. Middle East & Africa Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 43. Middle East & Africa Idiopathic Hypersomnia Treatment Market Share by Country (2018-2029)

Figure 44. Turkey Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 45. Saudi Arabia Idiopathic Hypersomnia Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 46. Takeda Pharmaceutical Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)

Figure 47. Teva Pharmaceutical Industries Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)

Figure 48. Jazz Pharmaceuticals Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)

Figure 49. BIOPROJET Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)

Figure 50. Avadel Pharmaceuticals Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)

Figure 51. GlaxoSmithKline Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)

Figure 52. Pfizer Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)

Figure 53. Theranexus Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)

Figure 54. Fisher and Paykel Healthcare Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)

Figure 55. Drive DeVilbiss Healthcare Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)

Figure 56. Merck Revenue Growth Rate in Idiopathic Hypersomnia Treatment Business (2018-2023)

Figure 57. Bottom-up and Top-down Approaches for This Report

Figure 58. Data Triangulation

Figure 59. Key Executives Interviewed

I would like to order

Product name: Global Idiopathic Hypersomnia Treatment Market Research Report 2023

Product link: <https://marketpublishers.com/r/G18FEE95CB25EN.html>

Price: US\$ 2,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G18FEE95CB25EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970